1. Home
  2. UPS vs REGN Comparison

UPS vs REGN Comparison

Compare UPS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Parcel Service Inc.

UPS

United Parcel Service Inc.

N/A

Current Price

$116.31

Market Cap

98.0B

Sector

Industrials

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$779.52

Market Cap

79.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UPS
REGN
Founded
1907
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.0B
79.4B
IPO Year
1999
1995

Fundamental Metrics

Financial Performance
Metric
UPS
REGN
Price
$116.31
$779.52
Analyst Decision
Buy
Buy
Analyst Count
20
23
Target Price
$110.95
$812.57
AVG Volume (30 Days)
5.7M
712.6K
Earning Date
04-28-2026
04-16-2026
Dividend Yield
5.76%
0.48%
EPS Growth
N/A
8.19
EPS
6.56
41.48
Revenue
N/A
$5,872,227,000.00
Revenue This Year
$1.79
$11.69
Revenue Next Year
$4.30
$10.12
P/E Ratio
$17.36
$18.91
Revenue Growth
N/A
20.82
52 Week Low
$82.00
$476.49
52 Week High
$123.70
$821.11

Technical Indicators

Market Signals
Indicator
UPS
REGN
Relative Strength Index (RSI) 56.35 49.61
Support Level $98.55 $731.65
Resistance Level $122.41 $786.67
Average True Range (ATR) 2.41 20.22
MACD -0.71 -1.18
Stochastic Oscillator 26.16 38.74

Price Performance

Historical Comparison
UPS
REGN

About UPS United Parcel Service Inc.

As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 65% of total revenue, while international package makes up 20%. Air and ocean freight forwarding and contract logistics make up the remainder.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: